

Iontophoresis as a possible therapy for digital ischaemia

Submission date 12/05/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/05/2010	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 29/07/2013	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Andrea Murray

Contact details
Clinical Sciences Building
Dept. of GI Sciences
Hope Hospital
Stott Lane
Salford
United Kingdom
M6 8HD

Additional identifiers

Protocol serial number
6621

Study information

Scientific Title
Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders

Acronym

Iontophoresis Study

Study objectives

Six patients with scleroderma (SSc) spectrum disorder, and associated digital ischaemia and/or ulceration, who are in hospital to receive intravenous (IV) vasodilation therapy, will be recruited for the study.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Salford and Trafford Research Ethics Committee approved (ref: 04/Q1404/209)

Study design

Single centre non-randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Skin, Musculoskeletal; Subtopic: Musculoskeletal (all Subtopics), Skin (all Subtopics);
Disease: Musculoskeletal, Dermatology

Interventions

Iontophoresis will be delivered over the whole finger. The iontophoresis dose will be 200 uA of 0.5% NaNP (diluted by volume in distilled water) for 5 mins, 4 times a day (but this will be reduced if troublesome tingling/paraesthesia occurs with this schedule) for 5 days (the duration of the iloprost treatment). The NaNP iontophoresis will be ADDITIONAL to the IV prostanoid therapy for which the patient was admitted.

Follow-up length: 0 months

Study entry: registration only

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Increase in perfusion; one laser Doppler image will be taken before and after treatment on days 1, 2 and 5 where possible.

Key secondary outcome(s)

1. Modified Scleroderma Health Assessment Questionnaire (SHAQ); these will be filled out by patients at the start and end of the 5 day treatment period
2. Patient opinion, measured at the end of the 5 day treatment period

Completion date

30/09/2010

Eligibility

Key inclusion criteria

1. A diagnosis of SSc (or of another scleroderma-spectrum disorder)
2. Severe digital ischaemia
3. Digital ulceration severe enough to require hospitalisation for intravenous prostanoid therapy
4. Aged 18 - 80 years, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Aged less than 18 or greater than 80 years
2. Pregnancy

Date of first enrolment

01/09/2006

Date of final enrolment

30/09/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Clinical Sciences Building
Salford
United Kingdom
M6 8HD

Sponsor information

Organisation
Salford Royal NHS Foundation Trust (UK)

ROR
<https://ror.org/019j78370>

Funder(s)

Funder type
Research organisation

Funder Name
Raynaud's and Scleroderma Association (UK)

Alternative Name(s)
RSA

Funding Body Type
Private sector organisation

Funding Body Subtype
Associations and societies (private and public)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2008		Yes	No